5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.


June 14

Weekly Gain

CardioNet (NASDAQ: BEAT  )



Questcor (UNKNOWN: QCOR.DL  )






Groupon (NASDAQ: GRPN  )



InvenSense (NYSE: INVN  )



Source: Barron's.

Let's start with CardioNet. The provider of wireless medical technology in diagnosing and monitoring cardiac arrhythmias struck a three-year deal with UnitedHealth Group that will cover all of CardioNet's monitoring modalities through all of UnitedHealth's affiliates. The insurance reimbursements will be great, but it's also about the validation of CardioNet's business.

Questcor Pharmaceuticals moved higher after acquiring the rights to Novartis' immune drug Synacthen. The drug, which has yet to be approved domestically, is used for the treatment of autoimmune and inflammatory conditions.

Avanir soared after Mizuho initiated coverage of the biotech with a buy rating. Avanir also moved higher earlier this month after the FDA approved an accelerated development pathway for its lead candidate. Shares would have to more than double from here to hit Mizuho's price target of $10.

Groupon also got slapped with a $10 price target. Deutsche Bank analyst Ross Sandler, who earlier had a $6 goal for the stock, sees the daily-deals leader as a major player in the booming mobile space.

Finally we have InvenSense on the move. The company emerged on the scene with its gyroscopes used for motion-tracking devices in video-game systems, but these days the real growth is coming from those same devices making their way into Android and iOS smartphones and tablets. Piper Jaffray put out a positive note on InvenSense, targeting $290 million in revenue this fiscal year, well ahead of the analyst average forecast of $256 million.

A few more winners
With so much of the financial industry getting bad press these days, it may time to get greedy when others are fearful. Not surprisingly, some of Warren Buffett's biggest investments are in the space. In The Motley Fool's free report "The Stocks Only the Smartest Investors Are Buying," you can learn about a small, under-the-radar bank that's too tiny for Buffett's billions. Too bad for Buffett, because it has better operating metrics than his favorites. Just click here to keep reading.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2491729, ~/Articles/ArticleHandler.aspx, 9/27/2016 8:34:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
AVNR.DL $0.00 Down +0.00 +0.00%
BEAT $18.70 Up +0.12 +0.65%
Cardionet CAPS Rating: ***
GRPN $5.33 Up +0.15 +2.90%
Groupon CAPS Rating: *
INVN $7.25 Down -0.05 -0.68%
InvenSense CAPS Rating: *****
QCOR.DL $0.00 Down +0.00 +0.00%
Questcor Pharmaceu… CAPS Rating: **